LOVE PHARMA – JOHNS HOPKINS UNIVERSITY PSILOCYBIN TRIAL ADVANCES TOWARD LAUNCH IN 2022
October 13, 2022
- Dr. Albert Garcia Romeu will serve as head researcher for the Love Pharma’s MicroDoz sponsored trial to be conducted at the Johns Hopkins Center for Psychedelic and Consciousness Research
- The MicroDoz Therapy team is sponsoring a study to evaluate the effectiveness of psilocybin in treating Cannabis Use Disorder in 12 patients conducted by Dr. Albert Garcia Romeu and colleagues
- This study builds upon the Company’s major research initiative, to identify and target addiction treatment solutions
VANCOUVER, BC, CANADA (October 13th , 2022) – LOVE Pharma Co. (“LOVE” and or “The Company”)(CSE: LUV) (FSE: G1Q0), the Company is pleased to provide the following update on the advancement of the previously announced trial focused upon clinical applications for psilocybin assisted therapy for addiction to be conducted at Johns Hopkins.
“LOVE is actively working to identify and assess biotechnology and pharmaceutical solutions to address addiction, with intent to grow its pharmaceutical presence in the underserved addiction treatment market,” said Mr. Zach Stadnyk, Love Pharma President and CEO. “Since acquiring MicroDoz, the LOVE team has worked diligently to design and prepare to launch this comprehensive study relating to the potential of psilocybin assisted treatment for cannabis use disorder, and we are excited to advance this initiative.”
The study will be led by Dr. Albert Garcia-Romeu and will help to establish consumer confidence and guide the development and use of psilocybin products for addiction treatment. Albert Garcia-Romeu, Ph.D. is a member of the Psychiatry and Behavioral Sciences faculty at the Johns Hopkins University School of Medicine, where he studies the effects of psychedelic drugs in humans, with a focus on psilocybin as an aid in the treatment of addiction. (https://www.hopkinsmedicine.org/profiles/details/albert-garciaromeu)
This pilot trial will serve as a foundation to advance the research to larger scale trials and drive future licensing and commercialization opportunities.
Johns Hopkins Study Highlights:
MicroDoz Therapy is sponsoring a study to test the effectiveness of psilocybin in treating Cannabis Use Disorder in 12 patients. The proposed study timeline includes the following, which is subject to potential changes
- Final regulatory approval and hiring of study coordinator – October-November
- Initial patient recruitment – December-January
- Complete patient treatment – Q1 2024
- Complete follow-ups – Q2-Q3 2024
Data generated in the study will be available to MicroDoz Therapy Inc., a wholly owned subsidiary of Love Pharma.
LOVE is excited to officially launch this research initiative at Johns Hopkins this Fall and will continue to update shareholders as milestones are achieved (for which there is no guarantee). Sponsoring a successful pilot trial will allow the company to advance further clinical research initiatives.
Zachary Stadnyk, CEO and Director
About Love Pharma Inc.
With a focus on the global sexual Health and Wellness markets, Love Pharma Inc. (CSE: LUV) (FSE: G1Q0) was founded in 2020, with a mission to bring to market innovative products that enhance sexual health and wellness while providing an improved quality of life. Love Pharma holds exclusive licenses to produce market, package, sell, and distribute patent-protected therapeutic and pharmaceutical products throughout Europe, the United Kingdom, and North America.
For further information, please contact:
Telephone: 1 (604) 343-2977
Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.
Certain statements contained in this release may constitute “forward–looking statements” or “forward-looking information” (collectively “forward-looking information”) as those terms are used in the Private Securities Litigation Reform Act of 1995 and similar Canadian laws. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated”, “anticipates” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Company’s current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. In particular, this release contains forward-looking information relating to the business of the Company, financing, and certain corporate changes. The forward-looking information contained in this release is made as of the date hereof and the Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward-looking information. The foregoing statements expressly qualify any forward-looking information contained herein.